UK Markets closed

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.00+0.26 (+2.04%)
At close: 1:00PM EST
Currency in USD

Valuation measures

Market cap (intra-day) 5608.59M
Enterprise value 3610.91M
Trailing P/E N/A
Forward P/E 1-5.60
PEG ratio (5-yr expected) 10.06
Price/sales (ttm)7.32
Price/book (mrq)10.13
Enterprise value/revenue 37.35
Enterprise value/EBITDA 6-4.47

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 326.26
52-week low 39.01
50-day moving average 311.45
200-day moving average 312.71

Share statistics

Avg vol (3-month) 3738.71k
Avg vol (10-day) 3521.03k
Shares outstanding 546.81M
Float 45.82M
% held by insiders 12.11%
% held by institutions 1106.09%
Shares short (12 Nov 2020) 46.17M
Short ratio (12 Nov 2020) 46.82
Short % of float (12 Nov 2020) 418.14%
Short % of shares outstanding (12 Nov 2020) 413.18%
Shares short (prior month 14 Oct 2020) 47.76M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)29 Sep 2020

Profitability

Profit margin -231.05%
Operating margin (ttm)-204.59%

Management effectiveness

Return on assets (ttm)-25.13%
Return on equity (ttm)-142.61%

Income statement

Revenue (ttm)83.11M
Revenue per share (ttm)1.82
Quarterly revenue growth (yoy)8.30%
Gross profit (ttm)42.29M
EBITDA -136.68M
Net income avi to common (ttm)-192.03M
Diluted EPS (ttm)-4.19
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)218.43M
Total cash per share (mrq)4.67
Total debt (mrq)220.75M
Total debt/equity (mrq)367.32
Current ratio (mrq)3.33
Book value per share (mrq)1.28

Cash flow statement

Operating cash flow (ttm)-114.18M
Levered free cash flow (ttm)-64.57M